Corrigendum to "Waste management-Cytokines, growth factors and cachexia" [Cytokine Growth Factor Rev. 17 (2006) 475-486] (DOI:10.1016/j.cytogfr.2006.09.006);Waste management-Cytokines, growth factors and cachexia

Cytokine and Growth Factor Reviews

Volumn 17, Issue 6, 2006, Pages 475-486

  Saini, Amarjit ^a   Nasser, Al Shanti ^a   Stewart, Claire E H ^a  

^a MANCHESTER METROPOLITAN UNIVERSITY   (United Kingdom)

Author keywords

Akt; Cachexia; Caspases; IGF I; TNF ; Ubiquitin

Indexed keywords

CYTOKINE; GROWTH FACTOR; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEASOME; PROTEIN KINASE B; SOMATOMEDIN; TUMOR NECROSIS FACTOR ALPHA; UBIQUITIN;

APOPTOSIS; CACHEXIA; CATABOLISM; CELL DEATH; DIET; EXERCISE; GENETIC TRANSCRIPTION; HOMEOSTASIS; HUMAN; INFLAMMATION; MUSCLE DEVELOPMENT; MUSCLE FUNCTION; MUSCLE HYPERTROPHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; SENESCENCE; SHORT SURVEY; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE; TISSUE REPAIR;

ANIMALIA;

EID: 33751233252     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2007.01.001     Document Type: Erratum

References (109)

1. MacDonald N., Easson A.M., Mazurak V.C., Dunn G.P., and Baracos V.E. Understanding and managing cancer cachexia. J Am Coll Surg 197 (2003) 143-161
2. Inui A. Cancer anorexia-cachexia syndrome: current issues in research and management. CA Cancer J Clin 52 (2002) 72-91
3. Muscaritoli M., Bossola M., Aversa Z., Bellantone R., and Rossi Fanelli F. Prevention and treatment of cancer cachexia: new insights into an old problem. Eur J Cancer 42 (2006) 31-41
4. Argiles J.M., Moore-Carrasco R., Fuster G., Busquets S., and Lopez-Soriano F.J. Cancer cachexia: the molecular mechanisms. Int J Biochem Cell Biol 35 (2003) 405-409
5. Tisdale M.J. Cancer cachexia: metabolic alterations and clinical manifestations. Nutrition 13 (1997) 1-7
6. Fanelli F., Cangiano C., Muscaritoli M., Conversano L., Torelli G., and Cascino A. Tumour-induced changes in host metabolism: a possible marker of neoplastic disease. Nutrition 11 (1995) 595-600
7. Bossola M., Muscaritoli M., Costelli P., et al. Increased muscle proteasome activity correlates with disease severity in gastric cancer patients. Ann Surg 237 (2003) 384-389
8. Vigano A., Bruera E., Jhangri G.S., Newman S.C., Fields A.L., and Suarez-Almazor M.E. Clinical survival predictors in patients with advanced cancer. Arch Intern Med 160 (2000) 861-868
9. Baracos V.E. Regulation of skeletal-muscle-protein turnover in cancer-associated cachexia. Nutrition 16 (2000) 1015-1018
10. Baracos V.E. Hypercatabolism and hypermetabolism in wasting states. Curr Opin Clin Nutr Metab Care 5 (2002) 237-239
11. Costelli P., and Baccino F.M. Cancer cachexia: from experimental models to patient management. Curr Opin Clin Nutr Metab Care 3 (2000) 177-181
12. Llovera M., Garcia-Martinez C., Lopez-Soriano J., et al. Protein turnover in skeletal muscle of tumour-bearing transgenic mice overexpressing the soluble TNF receptor-1. Cancer Lett 130 (1998) 19-27
13. Glass D.J. Molecular mechanisms modulating muscle mass. Trends Mol Med 9 (2003) 344-350
14. Szewczyk N.J., and Jacobson L.A. Signal-transduction networks and the regulation of muscle protein degradation. Int J Biochem Cell Biol 37 (2005) 1997-2011
15. Argiles J.M., Alvarez B., Carbo N., Busquets S., Van Royen M., and Lopez-Soriano F.J. The divergent effects of tumour necrosis factor-alpha on skeletal muscle: implications in wasting. Eur Cytokine Netw 11 (2000) 552-559
16. Barber M.D., Powell J.J., Lynch S.F., Fearon K.C., and Ross J.A. A polymorphism of the interleukin-1 beta gene influences survival in pancreatic cancer. Br J Cancer 83 (2000) 1443-1447
17. Kotler D.P. Cachexia. Ann Intern Med 133 (2000) 622-634
18. Wigmore S.J., McMahon A.J., Sturgeon C.M., and Fearon K.C. Acute-phase protein response, survival and tumour recurrence in patients with colorectal cancer. Br J Surg 88 (2001) 255-260
19. Mourkioti F., and Rosenthal N. IGF-1, inflammation and stem cells: interactions during muscle regeneration. Trends Immunol 26 (2005) 535-542
20. Prisk V., and Huard J. Muscle injuries and repair: the role of prostaglandins and inflammation. Histol Histopathol 18 (2003) 1243-1256
21. Tidball J.G. Inflammatory processes in muscle injury and repair. Am J Physiol Regul Integr Comp Physiol 288 (2005) R345-R353
22. Huard J., Li Y., and Fu F.H. Muscle injuries and repair: current trends in research. J Bone Joint Surg Am 84-A (2002) 822-832
23. Zoico E., and Roubenoff R. The role of cytokines in regulating protein metabolism and muscle function. Nutr Rev 60 (2002) 39-51
24. Meadows K.A., Holly J.M., and Stewart C.E. Tumor necrosis factor-alpha-induced apoptosis is associated with suppression of insulin-like growth factor binding protein-5 secretion in differentiating murine skeletal myoblasts. J Cell Physiol 183 (2000) 330-337
25. Pajonk F., and McBride W.H. The proteasome in cancer biology and treatment. Radiat Res 156 (2001) 447-459
26. Stewart C.E. The physiology of stem cells: potential for the elderly patient. J Musculoskelet Neuronal Interact 4 (2004) 179-183
27. Ferrucci L., and Guralnik J.M. Inflammation, hormones, and body composition at a crossroad. Am J Med 115 (2003) 501-502
28. Li Y.P., Lecker S.H., Chen Y., Waddell I.D., Goldberg A.L., and Reid M.B. TNF-alpha increases ubiquitin-conjugating activity in skeletal muscle by up-regulating UbcH2/E220k. FASEB J 17 (2003) 1048-1057
29. Pedersen M., Bruunsgaard H., Weis N., et al. Circulating levels of TNF-alpha and IL-6-relation to truncal fat mass and muscle mass in healthy elderly individuals and in patients with type-2 diabetes. Mech Ageing Dev 124 (2003) 495-502
30. Spiegelman B.M., and Hotamisligil G.S. Through thick and thin: wasting, obesity, and TNF alpha. Cell 73 (1993) 625-627
31. Argiles J.M., and Lopez-Soriano F.J. The role of cytokines in cancer cachexia. Med Res Rev 19 (1999) 223-248
32. Li Y.P., Schwartz R.J., Waddell I.D., Holloway B.R., and Reid M.B. Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-kappaB activation in response to tumor necrosis factor alpha. FASEB J 12 (1998) 871-880
33. Hoshino E., Pichard C., Greenwood C.E., et al. Body composition and metabolic rate in rat during a continuous infusion of cachectin. Am J Physiol 260 (1991) E27-E36
34. Lang C.H., Frost R.A., Nairn A.C., MacLean D.A., and Vary T.C. TNF-alpha impairs heart and skeletal muscle protein synthesis by altering translation initiation. Am J Physiol Endocrinol Metab 282 (2002) E336-E347
35. Buck M., and Chojkier M. Muscle wasting and dedifferentiation induced by oxidative stress in a murine model of cachexia is prevented by inhibitors of nitric oxide synthesis and antioxidants. EMBO J 15 (1996) 1753-1765
36. Ahmad S., Karlstad M.D., Choudhry M.A., and Sayeed M.M. Sepsis-induced myofibrillar protein catabolism in rat skeletal muscle. Life Sci 55 (1994) 1383-1391
37. Tessitore L., Costelli P., and Baccino F.M. Humoral mediation for cachexia in tumour-bearing rats. Br J Cancer 67 (1993) 15-23
38. Cao P.R., Kim H.J., and Lecker S.H. Ubiquitin-protein ligases in muscle wasting. Int J Biochem Cell Biol 37 (2005) 2088-2097
39. Lecker S.H., Solomon V., Mitch W.E., and Goldberg A.L. Muscle protein breakdown and the critical role of the ubiquitin-proteasome pathway in normal and disease states. J Nutr 129 (1999) 227S-237S
40. Argiles J.M., Pallares-Trujillo J., and Lopez-Soriano F.J. Role of the ubiquitin system in the etiology of cancer and other diseases. Med Clin (Barc) 111 (1998) 423-426
41. Hasselgren P.O., and Fischer J.E. The ubiquitin-proteasome pathway: review of a novel intracellular mechanism of muscle protein breakdown during sepsis and other catabolic conditions. Ann Surg 225 (1997) 307-316
42. Llovera M., Garcia-Martinez C., Agell N., Lopez-Soriano F.J., and Argiles J.M. TNF can directly induce the expression of ubiquitin-dependent proteolytic system in rat soleus muscles. Biochem Biophys Res Commun 230 (1997) 238-241
43. Hershko A., and Ciechanover A. The ubiquitin system. Annu Rev Biochem 67 (1998) 425-479
44. Gomes M.D., Lecker S.H., Jagoe R.T., Navon A., and Goldberg A.L. Atrogin-1 a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci USA 98 (2001) 14440-14445
45. Bodine S.C., Latres E., Baumhueter S., et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294 (2001) 1704-1708
46. Sandri M., Sandri C., Gilbert A., et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 117 (2004) 399-412
47. Centner T., Yano J., Kimura E., et al. Identification of muscle specific ring finger proteins as potential regulators of the titin kinase domain. J Mol Biol 306 (2001) 717-726
48. McElhinny A.S., Perry C.N., Witt C.C., Labeit S., and Gregorio C.C. Muscle-specific RING finger-2 (MURF-2) is important for microtubule, intermediate filament and sarcomeric M-line maintenance in striated muscle development. J Cell Sci 117 (2004) 3175-3188
49. Hengartner M.O. The biochemistry of apoptosis. Nature 407 (2000) 770-776
50. Denecker G., Vercammen D., Declercq W., and Vandenabeele P. Apoptotic and necrotic cell death induced by death domain receptors. Cell Mol Life Sci 58 (2001) 356-370
51. Belizario J.E., Lorite M.J., and Tisdale M.J. Cleavage of caspases-1, -3, -6, -8 and -9 substrates by proteases in skeletal muscles from mice undergoing cancer cachexia. Br J Cancer 84 (2001) 1135-1140
52. Du J., Wang X., Miereles C., et al. Activation of caspase-3 is an initial step triggering accelerated muscle proteolysis in catabolic conditions. J Clin Invest 113 (2004) 115-123
53. Nakagawa T., Zhu H., Morishima N., et al. Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta. Nature 403 (2000) 98-103
54. Dirks A., and Leeuwenburgh C. Apoptosis in skeletal muscle with aging. Am J Physiol Regul Integr Comp Physiol 282 (2002) R519-R527
55. Conley K.E., Jubrias S.A., and Esselman P.C. Oxidative capacity and ageing in human muscle. J Physiol 526 Pt 1 (2000) 203-210
56. Kwong L.K., and Sohal R.S. Age-related changes in activities of mitochondrial electron transport complexes in various tissues of the mouse. Arch Biochem Biophys 373 (2000) 16-22
57. Li P., Nijhawan D., Budihardjo I., et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91 (1997) 479-489
58. Green D.R., and Reed J.C. Mitochondria and apoptosis. Science 281 (1998) 1309-1312
59. Shiokawa D., Maruta H., and Tanuma S. Inhibitors of poly(ADP-ribose) polymerase suppress nuclear fragmentation and apoptotic-body formation during apoptosis in HL-60 cells. FEBS Lett 413 (1997) 99-103
60. Nagata S. Apoptosis by death factor. Cell 88 (1997) 355-365
61. Adhihetty P.J., and Hood D.A. Mechanisms of apoptosis in skeletal muscle. Basic Appl Myol 13 (2003) 171-179
62. McArdle A., Maglara A., Appleton P., Watson A.J., Grierson I., and Jackson M.J. Apoptosis in multinucleated skeletal muscle myotubes. Lab Invest 79 (1999) 1069-1076
63. Kinloch R.A., Treherne J.M., Furness L.M., and Hajimohamadreza I. The pharmacology of apoptosis. Trends Pharmacol Sci 20 (1999) 35-42
64. Schotte P., Declercq W., Van Huffel S., Vandenabeele P., and Beyaert R. Non-specific effects of methyl ketone peptide inhibitors of caspases. FEBS Lett 442 (1999) 117-121
65. MacEwan D.J. TNF ligands and receptors-a matter of life and death. Br J Pharmacol 135 (2002) 855-875
66. Coletti D., Yang E., Marazzi G., and Sassoon D. TNFalpha inhibits skeletal myogenesis through a PW1-dependent pathway by recruitment of caspase pathways. EMBO J 21 (2002) 631-642
67. Barton-Davis E.R., Shoturma D.I., Musaro A., Rosenthal N., and Sweeney H.L. Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function. Proc Natl Acad Sci USA 95 (1998) 15603-15607
68. Holly J.M., Perks C.M., and Stewart C.E. Overview of insulin-like growth factor physiology. Growth Horm IGF Res 10 Suppl A (2000) S8-S9
69. Stewart C.E., and Rotwein P. Growth, differentiation, and survival: multiple physiological functions for insulin-like growth factors. Physiol Rev 76 (1996) 1005-1026
70. Rommel C., Bodine S.C., Clarke B.A., et al. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat Cell Biol 3 (2001) 1009-1013
71. Harridge S.D. Ageing and local growth factors in muscle. Scand J Med Sci Sports 13 (2003) 34-39
72. Matsui T., Nagoshi T., and Rosenzweig A. Akt and PI 3-kinase signaling in cardiomyocyte hypertrophy and survival. Cell Cycle 2 (2003) 220-223
73. Kozma S.C., and Thomas G. Regulation of cell size in growth, development and human disease: PI3K, PKB and S6K. Bioessays 24 (2002) 65-71
74. Nader G.A. Molecular determinants of skeletal muscle mass: getting the "AKT" together. Int J Biochem Cell Biol 37 (2005) 1985-1996
75. Damen J.E., Liu L., Rosten P., et al. The 145-kDa protein induced to associate with Shc by multiple cytokines is an inositol tetraphosphate and phosphatidylinositol 3,4,5-triphosphate 5-phosphatase. Proc Natl Acad Sci USA 93 (1996) 1689-1693
76. Stambolic V., Suzuki A., de la Pompa J.L., et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95 (1998) 29-39
77. Wada T., Sasaoka T., Funaki M., et al. Overexpression of SH2-containing inositol phosphatase 2 results in negative regulation of insulin-induced metabolic actions in 3T3-L1 adipocytes via its 5′-phosphatase catalytic activity. Mol Cell Biol 21 (2001) 1633-1646
78. Crackower M.A., Oudit G.Y., Kozieradzki I., et al. Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell 110 (2002) 737-749
79. Scott P.H., Brunn G.J., Kohn A.D., Roth R.A., and Lawrence Jr. J.C. Evidence of insulin-stimulated phosphorylation and activation of the mammalian target of rapamycin mediated by a protein kinase B signaling pathway. Proc Natl Acad Sci USA 95 (1998) 7772-7777
80. Hara K., Maruki Y., Long X., et al. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110 (2002) 177-189
81. Hara K., Yonezawa K., Kozlowski M.T., et al. Regulation of eIF-4E BP1 phosphorylation by mTOR. J Biol Chem 272 (1997) 26457-26463
82. Nader G.A., Hornberger T.A., and Esser K.A. Translational control: implications for skeletal muscle hypertrophy. Clin Orthop Relat Res (2002) S178-S187
83. Hardt S.E., and Sadoshima J. Glycogen synthase kinase-3beta: a novel regulator of cardiac hypertrophy and development. Circ Res 90 (2002) 1055-1063
84. Haq S., Choukroun G., Kang Z.B., et al. Glycogen synthase kinase-3beta is a negative regulator of cardiomyocyte hypertrophy. J Cell Biol 151 (2000) 117-130
85. Stitt T.N., Drujan D., Clarke B.A., et al. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell 14 (2004) 395-403
86. Bolster D.R., Kimball S.R., and Jefferson L.S. Translational control mechanisms modulate skeletal muscle gene expression during hypertrophy. Exerc Sport Sci Rev 31 (2003) 111-116
87. Rennie M.J., Wackerhage H., Spangenburg E.E., and Booth F.W. Control of the size of the human muscle mass. Annu Rev Physiol 66 (2004) 799-828
88. Kimball S.R., Farrell P.A., and Jefferson L.S. Invited review: role of insulin in translational control of protein synthesis in skeletal muscle by amino acids or exercise. J Appl Physiol 93 (2002) 1168-1180
89. Proud C.G., and Denton R.M. Molecular mechanisms for the control of translation by insulin. Biochem J 328 Pt 2 (1997) 329-341
90. Birkenkamp K.U., and Coffer P.J. Regulation of cell survival and proliferation by the FOXO (Forkhead box, class O) subfamily of Forkhead transcription factors. Biochem Soc Trans 31 (2003) 292-297
91. Rena G., Guo S., Cichy S.C., Unterman T.G., and Cohen P. Phosphorylation of the transcription factor forkhead family member FKHR by protein kinase B. J Biol Chem 274 (1999) 17179-17183
92. Jagoe R.T., Lecker S.H., Gomes M., and Goldberg A.L. Patterns of gene expression in atrophying skeletal muscles: response to food deprivation. FASEB J 16 (2002) 1697-1712
93. Lecker S.H., Jagoe R.T., Gilbert A., et al. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J 18 (2004) 39-51
94. Yaffe D., and Saxel O. Serial passaging and differentiation of myogenic cells isolated from dystrophic mouse muscle. Nature 270 (1977) 725-727
95. Foulstone E.J., Huser C., Crown A.L., Holly J.M., and Stewart C.E. Differential signalling mechanisms predisposing primary human skeletal muscle cells to altered proliferation and differentiation: roles of IGF-I and TNFalpha. Exp Cell Res 294 (2004) 223-235
96. Stewart C.E., Newcomb P.V., Savage P.B., Dickens M., Tavare J., and Holly J.M. Increased, not decreased activation of the insulin-like growth factor (IGF) receptor signalling pathway during ceramide-induced apoptosis. Growth Horm IGF Res 9 (1999) 131-142
97. Cuvillier O., Pirianov G., Kleuser B., et al. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature 381 (1996) 800-803
98. Hannun Y.A. Functions of ceramide in coordinating cellular responses to stress. Science 274 (1996) 1855-1859
99. Jayadev S., Liu B., Bielawska A.E., et al. Role for ceramide in cell cycle arrest. J Biol Chem 270 (1995) 2047-2052
100. Jarvis W.D., Fornari Jr. F.A., Browning J.L., Gewirtz D.A., Kolesnick R.N., and Grant S. Attenuation of ceramide-induced apoptosis by diglyceride in human myeloid leukemia cells. J Biol Chem 269 (1994) 31685-31692
101. Xia Z., Dickens M., Raingeaud J., Davis R.J., and Greenberg M.E. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270 (1995) 1326-1331
102. Coroneos E., Wang Y., Panuska J.R., Templeton D.J., and Kester M. Sphingolipid metabolites differentially regulate extracellular signal-regulated kinase and stress-activated protein kinase cascades. Biochem J 316 Pt 1 (1996) 13-17
103. Verheij M., Bose R., Lin X.H., et al. Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Nature 380 (1996) 75-79
104. Raines M.A., Kolesnick R.N., and Golde D.W. Sphingomyelinase and ceramide activate mitogen-activated protein kinase in myeloid HL-60 cells. J Biol Chem 268 (1993) 14572-14575
105. McConkey D.J., and Orrenius S. Signal transduction pathways to apoptosis. Trends Cell Biol 4 (1994) 370-375
106. Macaluso A., and De Vito G. Muscle strength, power and adaptations to resistance training in older people. Eur J Appl Physiol 91 (2004) 450-472
107. Macaluso A., Nimmo M.A., Foster J.E., Cockburn M., McMillan N.C., and De Vito G. Contractile muscle volume and agonist-antagonist coactivation account for differences in torque between young and older women. Muscle Nerve 25 (2002) 858-863
108. Narici M.V., Maganaris C.N., Reeves N.D., and Capodaglio P. Effect of aging on human muscle architecture. J Appl Physiol 95 (2003) 2229-2234
109. Fiatarone M.A., Marks E.C., Ryan N.D., Meredith C.N., Lipsitz L.A., and Evans W.J. High-intensity strength training in nonagenarians. Effects on skeletal muscle. JAMA 263 (1990) 3029-3034